Loading...
•
Jun 30, 2021
Evelo Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021
Key Takeaways
Evelo Biosciences reported a net loss of $31.6 million for the second quarter of 2021, with cash and cash equivalents totaling $123.3 million as of June 30, 2021. The company is advancing its clinical development programs, including EDP1815 in psoriasis and atopic dermatitis, and expects multiple clinical data readouts over the next 6-12 months.
EDP1815 Phase 2b data in psoriasis is expected in 3Q 2021.
Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated in 3Q 2021.
Mark Plinio was appointed as Chief Commercial Officer.
Multiple clinical data readouts are expected over the next 6-12 months.
Evelo
Evelo
Forward Guidance
Evelo anticipates data from the Phase 2b dose-ranging trial and Phase 1b cohorts with tablets and capsules for EDP1815 in psoriasis to be reported in 3Q 2021. The company also expects to start the Phase 2 trial for EDP1815 in atopic dermatitis in 3Q 2021, with data anticipated in 3Q 2022. Interim data from the Phase 1b trial for EDP1867 in atopic dermatitis is expected in 4Q 2021. Clinical development for EDP2939 in inflammation and EDP1908 in oncology is planned to be initiated in 2022.